Dewpoint Therapeutics
Fabio Pucci is a Senior Director of Venture Investments at Leaps by Bayer since October 2021 and serves on the board of directors for several biotech companies, including Dewpoint Therapeutics, Lyterian Therapeutics, Mozart Therapeutics, Capstan Therapeutics, Indapta Therapeutics, Immunitas Therapeutics, and Boundless Bio. Additionally, Fabio Pucci acts as a board observer for Kojin Therapeutics. Engagement in academia includes a role as an adjunct professor for the "Business of Biotechnology" master's course at Northeastern University. Fabio Pucci holds an MBA from London Business School and a PhD in Cell/Cellular and Molecular Biology from The University of Edinburgh.
This person is not in the org chart
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.